文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

新型PS-OME miR130b-3p减轻肾脏缺血再灌注损伤后的炎症与损伤并改善生存

NOVEL PS-OME MIRNA130B-3P REDUCES INFLAMMATION AND INJURY AND IMPROVES SURVIVAL AFTER RENAL ISCHEMIA-REPERFUSION INJURY.
PubMed 文献 · Shock · 2023-08-18
一句话结论小鼠肾缺血再灌注模型中,静脉给予PS-OME miR130(12.5 nmol/只)可减轻肾损伤与炎症标志物、减少中性粒细胞浸润与凋亡、降低10天死亡率。

该研究为小鼠肾缺血再灌注(I/R)损伤模型,夹闭双侧肾蒂30 min后立即静脉给予PS-OME miR130 12.5 nmol/只或溶媒(PBS),24 h后检测血液与肾脏指标,另设10天生存观察。结果显示,PS-OME miR130显著降低血清尿素氮、NGAL、KIM-1、IL-6及肾组织NGAL、KIM-1、KC、MIP-2 mRNA表达,并显著减少中性粒细胞浸润、损伤严重度评分和凋亡;10天生存研究中治疗组死亡率较溶媒组显著降低。作者认为PS-OME miR130作为eCIRP拮抗性miRNA模拟物,有望作为标准治疗辅助手段开发为AKI新型疗法。

要点

  • 小鼠肾I/R模型(双侧肾蒂夹闭30 min)术后立即静脉给予PS-OME miR130 12.5 nmol/只,24 h后血清尿素氮、NGAL、KIM-1、IL-6较溶媒组显著降低。
  • 肾组织NGAL、KIM-1、KC、MIP-2 mRNA在I/R后升高,PS-OME miR130治疗组较溶媒组显著降低。
  • 组织学上PS-OME miR130组中性粒细胞浸润、损伤严重度评分及凋亡均较溶媒组显著减少。
  • 10天生存研究中,PS-OME miR130治疗组死亡率较溶媒组显著降低。
  • PS-OME miR130为eCIRP的内源性抑制剂miRNA 130b-3p的化学修饰模拟物,作者认为其有望作为标准治疗的辅助手段开发为AKI新型疗法。

适用人群与场景

  • C57BL/6雄性小鼠,肾缺血再灌注损伤模型(双侧肾蒂夹闭30 min)或假手术。

处置流程与药物剂量

  • 小鼠肾I/R模型建立后立即静脉给予PS-OME miR130,剂量12.5 nmol/只;对照给予等量溶媒(磷酸盐缓冲液)。
  • 给药24 h后采集血液和肾脏组织进行损伤与炎症指标分析;另设一组同样处理并观察10天生存。

研究设计与关键结果

  • 研究类型:小鼠肾缺血再灌注损伤模型实验,设溶媒对照。
  • 干预与对照:PS-OME miR130 12.5 nmol/只静脉给药 vs 溶媒(PBS),肾I/R后立即给药。
  • 24 h血清指标:溶媒组血尿素氮、NGAL、KIM-1、IL-6显著升高,PS-OME miR130组较溶媒组显著降低。
  • 肾组织mRNA:I/R后NGAL、KIM-1、KC、MIP-2升高,PS-OME miR130组较溶媒组显著降低。
  • 组织学:PS-OME miR130组中性粒细胞浸润、损伤严重度评分及凋亡较溶媒组显著减少。
  • 10天生存研究:PS-OME miR130组死亡率较溶媒组显著降低。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠肾I/R模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文为小鼠肾I/R模型实验,作者认为PS-OME miR130有望作为标准治疗的辅助手段开发为AKI新型疗法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction : Acute kidney injury (AKI) is a prevalent medical disorder characterized by a sudden decline in kidney function, often because of ischemia/reperfusion (I/R) events. It is associated with significant chronic complications, and currently available therapies are limited to supportive measures. Extracellular cold-inducible RNA-binding protein (eCIRP) has been identified as a mediator that potentiates inflammation after I/R injury. However, it has been discovered that miRNA 130b-3p acts as an endogenous inhibitor of eCIRP. To address the inherent instability of miRNA in vivo , a chemically modified miRNA mimic called PS-OME miR130 was developed. We hypothesize that administration of PS-OME miR130 after renal I/R can lead to reduced inflammation and injury in a murine model of AKI. Methods : C57BL/6 male mice underwent renal I/R by clamping of bilateral renal hilum for 30 min or sham operation. Immediately after closure, mice were intravenously administered vehicle (phosphate-buffered saline) or PS-OME miR130 at a dose of 12.5 nmol/mouse. Blood and kidneys were collected after 24 h for further analysis. Separately, mice underwent renal I/R and administered vehicle or treatment and, survival was monitored for 10 days. Results : After renal I/R, mice receiving vehicle showed a significant increase in serum markers of kidney injury and inflammation including blood urea nitrogen, NGAL, KIM-1, and IL-6. After treatment with PS-OME miR130, these markers were significantly decreased. Kidney tissue mRNA expression for injury and inflammation markers including NGAL, KIM-1, KC, and MIP-2 were increased after renal I/R; however, these markers showed a significant reduction with PS-OME miR130 treatment. Histologically, treatment with PS-OME miR130 showed a significant decrease in neutrophil infiltration and injury severity score, and decreased apoptosis. In the 10-day survival study, mice in the treatment group showed a significant reduction in mortality as compared with vehicle group. Conclusion : In a murine renal I/R model, the administration of PS-OME miR130, a direct eCIRP antagonistic miRNA mimic, resulted in the reduction of kidney inflammation and injury, and improved survival. PS-OME miR130 holds promise to be developed as novel therapeutic for AKI as an adjunct to the standard of care.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Vazquez G, Sfakianos M, Coppa G, et al. NOVEL PS-OME MIRNA130B-3P REDUCES INFLAMMATION AND INJURY AND IMPROVES SURVIVAL AFTER RENAL ISCHEMIA-REPERFUSION INJURY. Shock. 2023. PMID: 37594792. doi:10.1097/SHK.0000000000002211

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。